Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

SAILING is a Phase III, randomized, double-blind, double-placebo, multicenter, parallel-group, noninferiority study in antiretroviral treatment-experienced, integrase inhibitor-naive, HIV-1 ...

Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

The four main classes, which most people are treated with, target one of three viral proteins which control HIV’s lifecycle: reverse transcriptase, integrase and protease. Historically, most people ...

An integrase-deficient HIV-1 transcomplemented ... of a cellular protein that acts as a potent dominant-negative inhibitor especially of the late events of the HIV-1 life cycle provides exciting ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

Furthermore, members of newer classes of drugs such as chemokine (c-c motif) receptor 5 (CCR5) entry inhibitors and integrase inhibitors, which have recently been approved as part of combination ...

£35 means we can empower more people living with HIV to challenge stigma with our information workshops, videos and broadcasts. Raltegravir (Isentress) is an HIV-1 integrase strand-transfer inhibitor ...

Juluca combines GSK’s already approved integrase inhibitor Tivicay (dolutegravir) with Janssen’s non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine), to produce a regimen that ...

The latest major breakthrough, according to Streek, was in integrase inhibitors. The integrase enzyme plays an important role in the replication of HIV and is responsible for integrating the viral ...

D.V.M. Duane Grandgenett's laboratory has been studying retroviruses since 1970 and discovered the viral integrase (IN) in 1978 in avian retroviruses. IN is responsible for integration of the viral ...

fusion inhibitors, CCR5 antagonists and integrase strand transfer inhibitors (source). However, because they are unable to eradicate viral reservoirs, none of these drugs are curative and lifelong ...